FDA expands Fasenra approval to hypereosinophilic syndrome
Bottom line
AstraZeneca said the US FDA has approved Fasenra (benralizumab) for hypereosinophilic syndrome, or HES, adding a new indication for a biologic already used in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis. The approval follows positive results from the phase 3 NATRON trial, which enrolled 133 patients with FIP1L1::PDGFRA-negative HES and found benralizumab significantly reduced the risk of a first flare versus placebo when added to background therapy. In the trial, 19.4% of benralizumab-treated patients had an HES flare versus 42.4% on placebo, and the hazard ratio for time to first flare was 0.35. AstraZeneca had been building toward this label expansion for years, including orphan drug designation for HES in 2019. (nature.com)
Why it matters: For veterinary professionals, this is mainly a human-health market and immunology signal rather than a direct practice change. It underscores continued investment in eosinophilic disease pathways, steroid-sparing strategies, and targeted biologics for rare inflammatory conditions, all of which can influence comparative medicine, translational research, and future expectations from pet parents who follow specialty-drug news. It also highlights how companies are extending established monoclonal antibodies into adjacent eosinophil-driven diseases once clinical and regulatory evidence matures. (nature.com)
What to watch: Watch for updated FDA labeling, payer coverage decisions, and whether AstraZeneca pursues broader eosinophilic-disease expansions beyond HES. (accessdata.fda.gov)
Key facts
- Brand
- Fasenra
- Generic name
- benralizumab
- Company
- AstraZeneca
- New indication
- Hypereosinophilic syndrome (HES)
- FDA action
- US FDA approved
- Prior uses
- Severe eosinophilic asthma, and eosinophilic granulomatosis with polyangiitis
- Trial
- Phase 3 NATRON
- Sample size
- 133 patients
- Key result
- 19.4% on benralizumab had an HES flare versus 42.4% on placebo; hazard ratio 0.35
AstraZeneca’s Fasenra has picked up a new US FDA approval in hypereosinophilic syndrome, expanding the reach of benralizumab beyond its earlier uses in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis. The decision is tied to the phase 3 NATRON study, which showed the drug delayed time to first HES flare and lowered flare risk in patients with FIP1L1::PDGFRA-negative disease receiving background therapy. (nature.com)
The approval has been a long time coming. AstraZeneca began phase 3 development in HES years ago, with the NATRON trial listed as part of a broader push into rare eosinophilic diseases. The company also secured orphan drug designation for HES in 2019, signaling early regulatory interest in the indication. Before NATRON, benralizumab had already shown promise in a smaller phase 2 study and in long-term follow-up data for PDGFRA-negative HES, helping build the case for a larger registrational program. (astrazeneca.com)
The key efficacy data are notable for a rare-disease program. In the Nature Medicine report of NATRON, 133 patients were randomized to benralizumab 30 mg every four weeks or placebo for 24 weeks on top of background therapy. Benralizumab significantly reduced the risk of first flare, with a hazard ratio of 0.35 and a P value of 0.0024. HES flare occurred in 19.4% of patients on benralizumab compared with 42.4% on placebo. Most enrolled patients had idiopathic HES, and roughly three-quarters were already receiving systemic oral corticosteroids at baseline, which matters because steroid burden remains a major issue in long-term management. Adverse-event rates were similar between groups, and investigators said the safety profile was consistent with prior benralizumab experience. (nature.com)
That result fits with the broader clinical story around eosinophil depletion. Benralizumab targets the IL-5 receptor alpha and is designed to drive rapid, near-complete eosinophil depletion. Earlier long-term follow-up in PDGFRA-negative HES suggested durable eosinophil suppression, though some patients needed to return to monthly dosing after attempts to stretch treatment intervals. Trade coverage of the NATRON data also emphasized improvement across key secondary measures, including lower annualized flare rates and fewer treatment withdrawals. (astrazeneca.com)
Expert reaction in open-access sources was limited, but the published literature gives useful context. The NATRON paper positions benralizumab as another biologic option in a space where treatment has often relied on corticosteroids, immunosuppressants, cytotoxic drugs, and, in selected molecularly defined cases, imatinib. The authors also note that mepolizumab already has an HES approval, so AstraZeneca’s win is less about creating a category than strengthening competition within a rare but clinically difficult eosinophilic disease segment. That’s an important commercial and clinical distinction. (nature.com)
Why it matters: For veterinary professionals, this isn’t a companion-animal treatment story, but it is relevant as a signal about where immunology and biologics are heading. Eosinophil-targeted therapies are becoming more precise, and human rare-disease approvals often shape translational research priorities, specialty referral conversations, and pet parent expectations around monoclonal antibodies. It also reinforces a familiar pattern in drug development: once a biologic proves itself in one eosinophil-driven condition, companies move quickly to test adjacent indications with shared inflammatory mechanisms. (nature.com)
There’s also a practical market angle. Fasenra is already an established brand with infrastructure for specialty distribution, reimbursement support, and clinician familiarity in other eosinophilic diseases. That can make uptake faster than for a brand-new product, although real-world use in HES will still depend on final label language, payer criteria, and how clinicians position it relative to existing biologic and steroid-based options. As an inference from the trial population, the strongest early use may be in patients with recurrent flares or those for whom steroid toxicity is becoming a major management problem. (nature.com)
What to watch: Next steps include publication of the final FDA-approved prescribing language for HES, formulary and coverage updates, and any additional real-world data on steroid-sparing use, flare prevention, and patient selection. It’s also worth watching whether AstraZeneca can keep extending benralizumab across other eosinophilic disorders after mixed progress in adjacent diseases over the past several years. (accessdata.fda.gov)